ATIM-42. SAFETY AND EFFICACY OF AUTOLOGOUS DENDRITIC CELLS/TUMOR CELL ANTIGEN ADJUVANT THERAPY OF GLIOBLASTOMA MULTIFORME: RESULTS OF 59 CASES

ABSTRACT: Abstract In our translational research, an immunotherapeutic, ADCTA-G, has been developed to emphasize autologous tumor antigens, DC antigen processing/presentation, enhanced tumor immunogenicity and CTL induction. Two clinical trials, Phase I/II [2003-2005Taiwan DOH/MA 0910072504] and phase II [2005–2016 NIH NCT02772094], “Dendritic Cell(DC)-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme”, respectively enrolled 17 and 42 WHO Grade-IV glioblastomas. Every patient received peripheral blood apheresis for PBMNCs. Monocytes were used for derivation of 3-7x108 phagocytic dendritic cells (iDC). Autologous glioma cells grown out of surgical tumor specimen were irradiated and co-cultivated 1 to 2:1 with iDC to make a ADCTA-G lot. After surgical tumor de-bulking, 10 vac

SUBMITTER: Huang Y 

PROVIDER: S-EPMC6216147 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature